Antithrombin Market to Grow with a CAGR of 5.26% through 2030
Increasing prevalence of thrombotic disorders to
advancements in biotechnology and pharmaceuticals are expected to drive the
Global Antithrombin Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Antithrombin
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030”, the Global Antithrombin Market was valued at USD 782.03
Million in 2024 and is expected to reach USD 1066.23 Million by 2030 with a
CAGR of 5.26% during the forecast period. This can be attributed to research and development. Research and
development efforts in the field of antithrombin continue to advance. Ongoing
studies explore new therapeutic applications and formulations of antithrombin
products. These innovations offer the potential to expand the market by
addressing unmet medical needs and improving patient outcomes.
Moreover, as patents on some antithrombin products
expire, the market may witness the introduction of biosimilar versions.
Biosimilars, which are highly similar to reference biologic products, could
provide cost-effective alternatives, potentially driving competition and
influencing pricing strategies.
The initial phase of the COVID-19 pandemic had a
significant impact on the antithrombin market due to factors such as the
temporary closure of manufacturing facilities and disruptions in research and
development activities. However, the demand for antithrombin products has seen
a rapid rise in response to their increased use in treating COVID-19 patients. Several factors are propelling the growth of the
antithrombin market. This includes a growing incidence of coagulation disorders
and the increased use of diagnostic kits employing antithrombin. Antithrombin
plays a pivotal role in preventing excessive blood clotting, and its demand has
surged in surgical procedures, particularly in cases involving chronic
illnesses like heart and kidney diseases. During surgeries, antithrombin is
crucial in preventing the formation of blood clots. Therefore, the upswing in surgical
procedures due to the prevalence of chronic diseases and an uptick in cases of
antithrombin deficiency has led to a heightened demand for antithrombin,
thereby fostering market growth. For instance, according to a 2022 report by the
British Heart Foundation, 7.6 million individuals in the United Kingdom suffer
from heart and circulatory conditions. Moreover, these numbers are anticipated
to continue rising due to factors such as underlying heart and circulatory
issues, an aging and expanding population, among others. Consequently, the
substantial burden of heart and circulatory diseases is driving the demand for
surgical interventions, consequently increasing the usage of antithrombin and
serving as a catalyst for market growth during the study period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Antithrombin Market”
The Global Antithrombin Market is segmented into
usage, source, type, regional distribution, and company.
Based on its Usage, The Therapeutics Segment is set to be the fastest-growing segment throughout the projected period. Antithrombin is a vital treatment for conditions like hereditary antithrombin deficiency, which significantly increases the risk of blood clots and heart issues. This genetic condition affects about 50% of those with it, leading to frequent clotting events, particularly after adolescence, driving the demand for antithrombin therapy. Moreover, ongoing research into antithrombin deficiencies, including the use of low molecular weight heparin (LMWH) during pregnancy, is opening up new treatment avenues. As these innovations expand the applications of antithrombin drugs, the segment is expected to see rapid growth, becoming a key driver in the market.
Based on region, the Europe is the second-largest region in
the global antithrombin market in terms of market size and share. Several
factors contribute to Europe's strong position in the antithrombin market. The
region boasts a well-developed healthcare system, advanced medical
technologies, and a large pool of healthcare professionals experienced in the
treatment of thrombotic disorders, including deep vein thrombosis (DVT),
pulmonary embolism (PE), and other blood clot-related conditions.
The prevalence of thrombotic diseases is
high in European countries, largely due to lifestyle factors, an aging
population, and the increased incidence of chronic diseases. This growing
patient base contributes to the demand for antithrombin therapies as key
options in managing blood clotting and prevention. European countries have also
been early adopters of novel anticoagulant therapies, further driving market
growth. In addition, many leading pharmaceutical companies based in Europe have
developed and commercialized antithrombin products, reinforcing the region’s
prominence in this space. The European market is also
well-regulated, with strict standards for medical product approval and patient
safety. This regulatory landscape ensures that antithrombin therapies in the
region meet high efficacy and safety standards, increasing their market
acceptance and uptake among healthcare providers. Moreover, the European
Medicines Agency (EMA) has approved several key antithrombin drugs, which has
significantly contributed to the growth of the market. Another crucial factor driving the
market in Europe is the availability of specialized medical centers and
expertise in treating thrombotic conditions. European healthcare institutions
have adopted advanced diagnostic and treatment techniques, such as genetic
testing and personalized medicine, to improve the diagnosis and management of
thrombotic disorders. This has expanded the scope of antithrombin therapies and
elevated their role in managing not only common but also rare coagulation
disorders.
Major companies operating in Global Antithrombin Market
are:
- Grifols,
S.A.
- Takeda
Pharmaceutical Company Limited
- Octapharma
Brasil Ltda.
- LFB
USA, Inc.
- Endpoint
Health, Inc.
- Siemens
Healthineers AG
- Thermo
Fisher Scientific Inc
- BioCare,
Inc.
- F.
Hoffmann-La Roche Ltd
- Kedrion
S.p.A
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global antithrombin market is poised
for significant growth in the coming years, driven by rising awareness of
thrombotic disorders, an aging population, and the increasing incidence of
chronic diseases. Continued advancements in biotechnological research,
particularly in recombinant therapies, will likely expand the range of
available treatments. Additionally, the growing demand for personalized
medicine and improved drug delivery systems will enhance the market’s
potential. Regulatory advancements and improved healthcare access, particularly
in emerging markets, will also support market expansion. As research progresses
and novel applications for antithrombin products are explored, the market is
expected to experience substantial growth, offering new opportunities for
industry players”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Antithrombin Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Usage (Therapeutics,
Diagnostics, Research, Others), By Source (Human, Recombinant Goat Milk,
Others), By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs), By Region and Competition,
2020-2030F”, has evaluated
the future growth potential of Global Antithrombin Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Antithrombin Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com